Index of reports
> Cases with Epstein-Barr Virus Associated Lymphoproliferative Disorder (2)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Orthoclone Okt3 (Muromonab-CD3) where reactions include epstein-barr virus associated lymphoproliferative disorder. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Orthoclone Okt3 side effects in 55 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-01
Patient: 55 year old female
Reactions: Pleural Neoplasm, Fatigue, Pleural Effusion, Vascular Pseudoaneurysm, Protein Total Increased, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Omentum Neoplasm, Haemobilia, Renal Neoplasm, Cytomegalovirus Hepatitis, Pneumonia, Dyspnoea, Plasmacytoma, Pancytopenia, Ascites, Globulins Increased, Asthenia, Herpes Virus Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Prednisone TAB
Dosage: unk
Indication: Immunosuppression
Start date: 1987-08-01
End date: 1987-09-01
Methylpednisolone Sodium Succinate
Dosage: unknown dosage, taken for one month
Indication: Immunosuppression
Start date: 1987-07-01
End date: 1987-08-01
Prednisone TAB
Dosage: 10 mg, daily
Administration route: Oral
Start date: 1987-09-01
End date: 1988-02-01
Orthoclone Okt3
Dosage: unk
Indication: Immunosuppression
Prednisone TAB
Dosage: 100 mg, x4 days
Start date: 1988-02-01
End date: 1988-02-01
Prednisone TAB
Dosage: 20 mg, daily
Start date: 1988-02-01
End date: 1989-01-01
Cyclosporine
Indication: Immunosuppression
Possible Orthoclone Okt3 side effects in 46 year old female
Reported by a health professional (non-physician/pharmacist) from Japan on 2011-10-31
Patient: 46 year old female
Reactions: Anaemia, Epstein-Barr Virus Associated Lymphoproliferative Disorder
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Tacrolimus
Dosage: 4 to 6 ng/ml
Indication: Renal and Pancreas Transplant Rejection
Orthoclone Okt3
Indication: Renal and Pancreas Transplant Rejection
Mycophenolate Mofetil
Administration route: Oral
Indication: Renal and Pancreas Transplant Rejection
|